A G E A N D S E X R E L A T E D E F F E C T O N HbAlC L E V E L S I N C H I L D R E N W I T H I N S U L I N D E P E N D E N T D I A B E T E S M E L L I T U S (IDDM).
I n a nationwide s c r e e n i n g f o r HbAIC i n D e n m a r k a l l 2 2 d i a b e t i c paediatric d e p a r t m e n t s participated. D ur i n g a p e r i o d o f 4 m o n t h s a t o t a l n u m b e r o f 791 c h i ld r e n (approximately 75% o f total) w a s included. A m o n g t h e s e 3 1 9 w e r e < 1 2 y a n d 4 7 2 b e t w e e n 1 2 a n d 18y. M e a n HbAlc for c h i l d r e n 2 1 2 y w a s 8.9% k1.5 (SD), m e a n i n s u l l n d o s a g e b e i n g 0.70 U/kg/24h, r a n g e 0.04-2.24 U/kg/24h. F o r c h i l d r e n between 1 2 a n d 1 8 y m e a n HbAlC w a s 9.4% %~.o(sD) (compared t o child r e n 5 1 2 y , p<0.001) m e a n i n s u l i n d o s i s b e i n g 0.85 U/kg/24h, r a n g e 0.00-3.24 U/kg/24h. A m o n g t h e 3 1 9 c h i l d r e n <12y, 1 7 4 w e r e b o y s a n d 1 4 5 w e r e girls. F o r b o t h groups m e a n HbAlC w a s 8.9 +1.5(SD). M e a n ins u l i n d o s a g e f o r b o y s w a s 0.66 U/kg/24h in c o n t r a s t t o 0.74 U/kg/24h f o r t h e girls. I n t h e g r o u p o f c h i ld r e n b e t w e e n 1 2 a n d 1 8 y m e a n HbAlc,among 2 5 0 b o y s w a s 9.5% ~~. o ( s D ) a n d f o r t h e remalnlng 2 2 2 g i r l s 9.9% f-1.9(~~) (p<0.001). I n s u l i n d o s i s w a s a g a i n c o n s i s t e n t l y h i g h e r f o r t h e g i r l s b e i n g 0.89 U/kg/24h c o m p a r e d t o 0.80 U/kg/24h f o r t h e boys. I n s p i t e o f increased i n s u l i n d o s a g e HbAlc increased w i t h a g e e s p e c i a l l y i n girls, suggesting a g e a n d s e x r e l a t e d c h a n g e s i n i n s u l i n sensitivity.
E.Vicens-Calvet, J.M. Cuatrecasas* (Introd. by I : . Viccns-Calvet). for the Study Collaborative Croup.
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Hospital Infantil Val1 ~'Hebron .Bi~rcelona. Kabi-Fides. Barcelona. SPANISI1 llULT1CENTRIC TRIAL ON SOMATREEI.
Uuring 1985-86 a multricentric trial to evaluate the safety and efficacy of Somatrem (SomatonormR) in children with growth hormone deficiency (GHD) was performed in Spain. 49 patients "new" as well as previously treated ("old"), with peak plasma hGH <7ng/ml height SD <-2.0 for chronological age (CA), growth velocity (CV) <4 cms/year, bone age (BA) <10 "years" in girls and 11 "years" in boys and idiopathic wcre involved in the trial. Dosage was 4 IU, 3 times a week i.m. EFFICACY: In "new" patients (N=21) GV changed from 3.39 cm/yr to 9.22 in the "young group" (CA<lO yrs) and from 2.52 to 6.62 in the "prepuberal" group (CA:10-16 yrs). In "old" patients (N=28), the majority of them, irregularly treated, the change in GV was from 4.8 cm/yr to 6.62 ("young group") and 3.15 to 6.02 (~r e~u b e r a l group). BA evolved parallely to C.A. with an improvement oi adult heigth prognosis. SI\FETY: The study of IrGH antibodies (IIGH-ab) in new patients showed a 29% of positive cases from the end of first quarter reaching a plateau between 36.6-28.5% later. ln the "old" group the percentage was significantly less. The Binding capacity of hCN-ab was very lov (M=O.Oj mg/l) E.coli polypeptide-ab fluctuated througliout trentment with no clear correlation with IrGII-ab. CONCLUSION: Som~itrcm is as erfective in patients with GllD as pit-h(:H was .~nd is a safe product since the ab found produce no deleterious metabolic effects and do not interfere with growth. 
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England.
TREATMENT OF HYPOPITUITARISM WITH RECOMBINANT MET-HGH (LILLY)
Recombinant Met-HGH (Lilly) has been used to treat 22 children with hypopituitarism. Mean age 7.1 yrs (range 3.7-12.1). 14 boys, 8 girls. In 16 children, an isolated GH deficiency was present. One child withdrew from treatment after 6 months, the remainder completed a minimum of 1 year. Met-HGH was given by SC injection, in 3 doses per week. each of 0.06mg/kg body weight, up to a maximum of B.Omg/week. The growth response is summarised below, (A = pretreatment, 8 = 1 year):
Ht 
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Switzerland representing 14 European centers, and Nordisk Gentofte, Denmark.
RESULTS OF TREATMENT WITH RECOMBINANT IHUMAN GROWTH HORMONE WITHOUT METHIONINE (r-hGH) IN PATIENTS (PTS) WITH GROWTH HORMONE DEFICIENCY (GHD)
. 255 pts with GHD (180 boys.75 girls, age 0.5-19.9(11.1+/-3.7), bone age 0-17(8.9+/-3.5)yrs. height SDS for chronologic age -2.8 +/-1.0) are currently treated with r-hGH sc(12.6+/-1.81U and 5.8 +/-I .3 injectionslweek).By mid-april,l81 pts had been treated for 3 , 89 for 6 , 27 for 9,and 1 1 for 12 months. 122 had isolated GHD, the others additional defects with adequate replacement(includ~ng 29 craniopharyngeomas , 19 other organi L causes and irrad~ation) . 93 had been transferred from p~t -or met-hGH. Routine blood analyses were normal before and on treatment.W~th exception of mild local burning, no side-effects were noted.Mean he~ght velocities (cmlyr, 3 month per~ods,SEM 0.2-0.9) were: Patients: all new transfer isol. comb. organic * ** GHD GHD a1 1 cran. ~rrad. basal(6m) 4.6 3.6 3.0 6.8 4.9 3.7 3.0 2.3 3.0 0 -3 m 9.0 9.4 10.4 6.8 7.8 10.4 9.4 10.2 9.0 3 -6 m 7.9 9.3 8.2 6.4 7.7 8.4 6 -9 m 7.3 8.3 7.2 7.0 7.3 7.4 * = 6 m 1 n t e r v a l 9-12m 8.1 8.7 7.2 8.9 5.5 9.1 **=nointerval IGFl ~ncreased from 14(6-26) to 25(12-47)nmo1/1(6m,without transfer**). hGll antibodies were found in 2 new (3-9 months) and 14 transfer pts(before r-hGH).E.col~ prote~n a n t~b o d~e s did not increase. It is concluded that r-hGI1 I S effective and safe in GIHD. P. Stubbe1, N. Stahnke2 and study group. Department of Pediatrics, University of ~oettingen' and Hamburg2 FRG.
R-HGH OF MAM~ALIAN CELL ORIGIN FOR THE TREATMENT OF GROWTH HORMONE (GH) DEFICIENCY IN CHILDREN.
Biogenetically produced authentic Gti (r-HGH) of mammalian cell origin was used in a multicenter treatment trial involving GH deficient children fron~ Austria, FRG, GCR and Switzerland after approval by ethical committees. GH was applied s.c. daily in a dose of 12 U/m2/week. Previously with GH treated (group T) and untreated (group U) patients were included. 65 patients met the selection criteria. Group U consisted of 20 males and 9 females, mean age 7.59t4.1 (SD) y, mean bone age(BA) 5.12t3.43 y. Group T enclosed 28 males, 8 females, mean age 9.66 ? 3.48 y, mean BA 6.57 1 3.01 y , pituitary GH was stopped for a period of time before r-HGH started. Results: After 6 months of treatment: Group U: Mean growth velocity increased from 3.06 + 0.81 to 10.26 t 2.5 cmly, mean height standard deviation score (SDS) for age was reduced from -3.45 11.27 to -2.97 t 1 .I and height age (HA): BA ratio increased from 1.02t0.24 to 1.1210.33. Group T: Growth velocity increased from 3.16c 1.98 to 8 . 8~ 2.35 cm/y, mean height SOS was reduced from -2.73t 1.91 to -2.42t1.76. HA: BA ratio improved from 0.97t0.27 to 1.08t0.26. In both groups Somatomedin C levels rose. One of 65 children developed GH antibodies, no antibodies to non r-HGH-protein could be detected. No clinically visible side effects were observed. Conclusion: This new type of r-HGH is effective and an alternative to r-HGH produced in E. coli bacteria. Biosynthetic lron~ologous human growth hormone (rccombinant DPln) produced by Eli Lilly was given to 81 childrcn trcated for growth hormone deficiency (GHD) in 26 centers. Crowth improved in all of them: 25 newly diagnosed patients increased their growth rate from 3.6 5 1.7 to 11.9 + 2.0 cm/y. 14 patients transferred from pituitary to b1osynthct.i~ hGfl continued to grow with a velocity of 5.7 5 2.2 cm/y compared to 5.0 2 3.3 cm/y when qivcri pit.-hGH. 42 patients with GHD receiving biosynth. hGll aftcr an interruption of therapy for approx.
one year grew with a velocity of 8.1 + 2.0 cm/y on biosynth.
hGH after a catch-down growth of 1.3 &n/y from a pit.-hGH induced growth ratc of 7.2 + 2.1 cm/y. The loss of growth -durinq the interruption was not compensaied for by catch-up growth. Therefore, any interruption of therapy may worsen t.hc height prognosis. No side effects were observed and no specific antibodies against biosynth. hGH dcvcloped during thcrapy. Antibody-titers against E-Coli peptidfs remained unchanged during thcrapy. In conclusion, therapy with biosynthetic homoloyous hGH is as effective as thcrapy with pit.-hGH and is safe. Therapy with hGH should not be interrupted during childhood and adolescence.
